Internal Medicine Department, Medical Specialities Department, King Fahad Medical City, Riyadh, Kingdom of Saudi Arabia.
Dermatology Department, King Fahad Medical City, Riyadh, Kingdom of Saudi Arabia.
Adv Rheumatol. 2024 Apr 29;64(1):34. doi: 10.1186/s42358-024-00371-1.
Psoriasis (PsO) is an immune-mediated chronic inflammatory disease that results in severe outcomes that impact the patient's quality of life and work productivity. We investigated the effectiveness of secukinumab in patients with chronic plaque psoriasis and psoriatic arthritis (PsA) over a 12-month period.
This was a longitudinal, retrospective study of the medical records of 81 patients with psoriasis and/or psoriatic arthritis who had been treated with secukinumab for at least 12 weeks.
The Psoriasis Area Severity Index (PASI), Body Surface Area (BSA) percentage, and Dermatology Quality of Life Index (DLQI) among patients with PsO and PsO-PsA showed a statistically significant decrease from baseline over 12 months by approximately 9.86, 19.3%, and 9.7, respectively (p values < 0.001 for each). Moreover, there was a statistically significant decrease in the overall Disease Activity in Psoriatic Arthritis score (DAPSA) by approximately 22.35 from baseline over 12 months of treatment (p < 0.001). Considering the patients who started secukinumab 12 months or more prior to the study cutoff date, the 12-month retention rate was 85%.
In a Saudi real-world setting, secukinumab proved to be an efficient medication with high efficacy and retention rates.
银屑病（PsO）是一种免疫介导的慢性炎症性疾病，会导致严重后果，影响患者的生活质量和工作生产力。我们研究了司库奇尤单抗在慢性斑块状银屑病和银屑病关节炎（PsA）患者中的疗效，为期 12 个月。
这是一项对至少接受司库奇尤单抗治疗 12 周的 81 例银屑病和/或银屑病关节炎患者的病历进行的纵向、回顾性研究。
银屑病患者和银屑病关节炎患者的银屑病面积严重程度指数（PASI）、体表面积（BSA）百分比和皮肤病生活质量指数（DLQI）在 12 个月内分别显著下降了约 9.86、19.3%和 9.7%（p 值均<0.001）。此外，治疗 12 个月后，整体银屑病关节炎疾病活动度评分（DAPSA）总体下降了约 22.35（p<0.001）。考虑到在研究截止日期前 12 个月或更早开始使用司库奇尤单抗的患者，12 个月的保留率为 85%。
在沙特的真实环境中，司库奇尤单抗被证明是一种高效、保留率高的药物。
